Chemomab Therapeutics Ltd DRC (CMMB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.70 (-3.57%), Market cap $0.01B, 52-week low–high $0.87 ~ $3.50.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Financial statements, price targets, institutional (13F) holdings and related news for Chemomab Therapeutics Ltd DRC are updated in real time on BlackAll Trade.
Chemomab Therapeutics Ltd DRC trades at $2.70 (-3.57%). Real-time quotes and charts are available on BlackAll Trade.
Chemomab Therapeutics Ltd DRC has a market cap of about $0.01B.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product c